Ignite Creation Date:
2024-05-06 @ 5:41 PM
Last Modification Date:
2024-10-26 @ 2:33 PM
Study NCT ID:
NCT05396391
Status:
RECRUITING
Last Update Posted:
2023-07-20
First Post:
2022-05-19
Brief Title:
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
Sponsor:
SUNHOChinaBioPharmaceutical CO Ltd
Organization:
SUNHOChinaBioPharmaceutical CO Ltd
Study Overview
Official Title:
A Phase IIIa Clinical Trial to Evaluate the Safety Tolerability and Preliminary Effectiveness of IAP0971 in Patients With Advanced Malignant Tumors
Status:
RECRUITING
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase I Clinical Trial to Evaluate the Safety Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors
Detailed Description:
The study includes three phases dose escalation Phase Ia dose extension Phase Ib and clinical exploration Phase IIaFirst the Phase Ia dose escalation will be carried out After finishing the Phase 1athe Phase Ib dose extension study can be carried out in the MTD dose which can be achieved from Phase 1a After Phase Ia Ib are completed and RP2D is obtained Phase IIa clinical exploratory research can be carried out
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None